Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 4
2006 1
2007 2
2008 2
2009 4
2010 2
2011 3
2012 5
2013 1
2014 1
2015 2
2016 5
2017 4
2018 8
2019 10
2020 5
2021 12
2022 14
2023 5
2024 8
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.
Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, Bilancia R, Keni M, Popat S, O'Brien M, Tokaca N, Maskell N, Stadon L, Fennell D, Nelson L, Edwards J, Tenconi S, Socci L, Rintoul RC, Wood K, Stone A, Muthukumar D, Ingle C, Taylor P, Cove-Smith L, Califano R, Summers Y, Tasigiannopoulos Z, Bille A, Shah R, Fuller E, Macnair A, Shamash J, Mansy T, Milton R, Koh P, Ionescu AA, Treece S, Roy A, Middleton G, Kirk A, Harris RA, Ashton K, Warnes B, Bridgeman E, Joyce K, Mills N, Elliott D, Farrar N, Stokes E, Hughes V, Nicholson AG, Rogers CA; MARS 2 Investigators. Lim E, et al. Lancet Respir Med. 2024 Jun;12(6):457-466. doi: 10.1016/S2213-2600(24)00119-X. Epub 2024 May 10. Lancet Respir Med. 2024. PMID: 38740044 Free PMC article. Clinical Trial.
BACKGROUND: Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemot …
BACKGROUND: Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated i …
Pleural mesothelioma.
Fennell DA, Sekido Y, Baas P, Husain AN, Curioni-Fontecedro A, Lim E, Opitz I, Simone CB 2nd, Brims F, Wong MC. Fennell DA, et al. Nat Rev Dis Primers. 2025 Aug 7;11(1):56. doi: 10.1038/s41572-025-00640-3. Nat Rev Dis Primers. 2025. PMID: 40775245 Review.
The incidence of mesothelioma increased globally during the late twentieth century, correlating with the use of asbestos, and it continues to rise in some regions. ...Patients with mesothelioma commonly present with fatigue, dyspnoea and/or cough caused by pleural e …
The incidence of mesothelioma increased globally during the late twentieth century, correlating with the use of asbestos, and it cont …
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM. Scherpereel A, et al. Eur Respir J. 2020 Jun 11;55(6):1900953. doi: 10.1183/13993003.00953-2019. Print 2020 Jun. Eur Respir J. 2020. PMID: 32451346 Free article.
The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on m …
The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS) …
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Fennell DA, et al. Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656227 Free PMC article. Clinical Trial.
BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-P …
BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma wh …
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
Carbone M, Pass HI, Ak G, Alexander HR Jr, Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, Churpek JE, Dianzani I, De Rienzo A, Emi M, Emri S, Felley-Bosco E, Fennell DA, Flores RM, Grosso F, Hayward NK, Hesdorffer M, Hoang CD, Johansson PA, Kindler HL, Kittaneh M, Krausz T, Mansfield A, Metintas M, Minaai M, Mutti L, Nielsen M, O'Byrne K, Opitz I, Pastorino S, Pentimalli F, de Perrot M, Pritchard A, Ripley RT, Robinson B, Rusch V, Taioli E, Takinishi Y, Tanji M, Tsao AS, Tuncer AM, Walpole S, Wolf A, Yang H, Yoshikawa Y, Zolondick A, Schrump DS, Hassan R. Carbone M, et al. J Thorac Oncol. 2022 Jul;17(7):873-889. doi: 10.1016/j.jtho.2022.03.014. Epub 2022 Apr 21. J Thorac Oncol. 2022. PMID: 35462085 Free PMC article. Review.
The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. …
The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal …
Novel insights into mesothelioma biology and implications for therapy.
Yap TA, Aerts JG, Popat S, Fennell DA. Yap TA, et al. Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Nat Rev Cancer. 2017. PMID: 28740119 Review.
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. ...However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic str …
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. ...However, the past 5 years …
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
Zhang M, Bzura A, Baitei EY, Zhou Z, Spicer JB, Poile C, Rogel J, Branson A, King A, Barber S, Kamata T, Dzialo J, Harber J, Greystoke A, Nusrat N, Faulkner D, Sun Q, Nolan L, Hahne JC, Scotland M, Walter H, Darlison L, Morgan B, Bajaj A, Brookes C, Hollox EJ, Lubawska D, Jama M, Griffiths G, Nakas A, Kutywayo K, Luo JL, Klampatsa A, Cooper A, Halder K, Wells-Jordan P, Zhou H, Dudbridge F, Thomas A, Richards CJ, Pritchard C, Yang H, Barer M, Fennell DA. Zhang M, et al. Nat Commun. 2024 Aug 21;15(1):7187. doi: 10.1038/s41467-024-49842-5. Nat Commun. 2024. PMID: 39168966 Free PMC article. Clinical Trial.
Malignant mesothelioma is a rare tumour caused by asbestos exposure that originates mainly from the pleural lining or the peritoneum. ...In summary, a model is proposed in which both intrinsic and extrinsic determinants in mesothelioma cooperate to modify the …
Malignant mesothelioma is a rare tumour caused by asbestos exposure that originates mainly from the pleural lining or the peri …
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.
Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Tsao MS, et al. J Thorac Oncol. 2019 Oct;14(10):1704-1717. doi: 10.1016/j.jtho.2019.06.020. Epub 2019 Jun 28. J Thorac Oncol. 2019. PMID: 31260832 Free article.
The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity …
The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate mak …
Immunotherapy approaches for malignant pleural mesothelioma.
Fennell DA, Dulloo S, Harber J. Fennell DA, et al. Nat Rev Clin Oncol. 2022 Sep;19(9):573-584. doi: 10.1038/s41571-022-00649-7. Epub 2022 Jul 1. Nat Rev Clin Oncol. 2022. PMID: 35778611 Review.
Predictive biological features that underpin response to ICIs remain poorly understood; however, insights into the immune microenvironment and genomic landscape of mesothelioma as well as into their association with response or acquired resistance to ICIs are emerging. ... …
Predictive biological features that underpin response to ICIs remain poorly understood; however, insights into the immune microenvironment a …
98 results